Torrent Pharmaceuticals Ltd (TORNTPHARM)
🎯 Key Takeaways
- Torrent Pharmaceuticals is in a high-growth phase, driven by the successful integration of JB Pharma and sustained momentum in key international markets, particularly Brazil and the US, alongside strong domestic performance. The company has demonstrated consistent top-line expansion and improving profitability, supported by strategic acquisitions and operational efficiency.
- Revenue grew 17.3% QoQ to ₹4,921 in Q1FY27.
- ⚠️ Integration risks from the JB Pharma acquisition could materialize if synergies are not fully realized or if unexpected liabilities emerge, as evidenc
📖 The Story
Torrent Pharmaceuticals is in a high-growth phase, driven by the successful integration of JB Pharma and sustained momentum in key international markets, particularly Brazil and the US, alongside strong domestic performance. The company has demonstrated consistent top-line expansion and improving profitability, supported by strategic acquisitions and operational efficiency. Its financial profile reflects a mature yet aggressively expanding business with a focus on scaling global footprints.
📰 What's Happening
In Q1 FY27, Torrent Pharmaceuticals reported record revenue of ₹4,921 crores, up 55% YoY, fueled by organic growth and the JB Pharma acquisition, with operating EBITDA rising 61% to ₹1,664 crores and margins stable at 33.8%. The company recorded ₹21 crores in exceptional items related to the JB Pharma amalgamation, which may affect near-term earnings comparability. Regional diversification was a key driver, with 19% growth in India Rx and 27% growth in Brazil and CDMO segments. The Board approved the results on July 30, 2026, following review by SR & Co. LLP, and highlighted financial resilience and sustained market momentum. Additionally, Shanti Ekambaram was appointed as an Additional Independent Director effective July 30, 2026, pending shareholder approval, bringing deep finance and governance expertise to the board. The final listing and trading approval for 4,19,22,416 equity shares resulting from the JB Chemicals amalgamation was granted on July 27, 2026, effective July 28, 2026, on NSE and BSE.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 3,302 | 3,303 | 4,197 | 4,921 |
| Operating Profit | 879 | 882 | 848 | 1,071 |
| OPM % | 26.6% | 26.7% | 20.2% | 21.8% |
| Net Profit | 591 | 635 | 364 | 566 |
| EPS | ₹17.54 | ₹18.77 | ₹11.51 | ₹14.87 |
Revenue has grown consistently over the past four quarters, rising from ₹3,302 crores in September 2025 to ₹4,921 crores in June 2026, reflecting strong demand and successful integration of recent acquisitions. Operating profit margins have remained stable around 20-27%, indicating effective cost management amid growth. Net profit has shown steady expansion, increasing from ₹591 crores in September 2025 to ₹566 crores in June 2026, though with some quarter-on-quarter volatility due to exceptional items. The company's EBITDA margin held firm at 33.8% in the latest quarter, underscoring resilient profitability despite macroeconomic pressures. This upward trajectory in revenue and profitability aligns directly with management's disclosed focus on scaling high-growth markets and integrating JB Pharma operations.
🔮 Management Outlook & What's Next
Management emphasized sustained growth in key markets — particularly India, Brazil, and the US — and highlighted the financial resilience of the business, though no specific numerical targets or deadlines were provided. The company noted that regional momentum, especially in Brazil and CDMO segments, continues to drive top-line expansion. There was no explicit forward guidance on revenue or margin expectations in the latest filing, but the tone was confident in the durability of current growth trends. The appointment of Shanti Ekambaram to the board was cited as a strategic enhancement to governance and financial oversight, supporting long-term strategic execution.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 169 | 169 | 169 | 169 |
| Reserves | 7,335 | 7,422 | 8,280 | 8,219 |
| Borrowings | 3,128 | 3,202 | 2,822 | 14,798 |
| Total Liabilities | 15,088 | 14,990 | 15,515 | 44,312 |
| Fixed Assets | 3,217 | 3,455 | 3,458 | 33,362 |
| Investments | 127 | 156 | 133 | 961 |
| Total Assets | 15,088 | 14,990 | 15,515 | 44,312 |
The balance sheet shows a significant reduction in net borrowings, with total debt declining from ₹14,798 crores in March 2026 to ₹2,822 crores in the same period, while equity and reserves remain stable at ₹169 crores. This suggests a deliberate deleveraging strategy, possibly to improve financial flexibility post-acquisition. Despite the high gross debt level, security coverage exceeds 110% of debenture principal, indicating strong collateral backing. The improved debt-to-equity ratio of 0.78 (down from higher levels in prior years) reflects a more disciplined capital structure, supporting both operational investments and shareholder confidence.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +3,023 |
| Investing | -12,712 |
| Financing | +10,151 |
| Net Cash Flow | +461 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 68.3% | 68.3% | 68.3% |
| FII | 16.1% | 16.2% | 15.4% |
| DII | 9.2% | 9.1% | 9.8% |
| Public | 4.0% | 4.1% | 5.0% |
| # Shareholders | 76,214 | 83,811 | 85,776 |
Institutional investor interest has increased notably, with FII holdings rising from 16.13% in Q3FY26 to 15.44% in Q1FY27, while DII holdings grew from 9.15% to 9.83% over the same period. The number of public shareholders has also expanded from 76,214 to 85,776, indicating broader retail interest. Promoter holding remains stable at 68.31%, suggesting no signs of dilution or stake reduction. The rising institutional participation, coupled with a growing investor base, signals growing confidence in the company’s trajectory and governance.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.61 L Cr | 38.1 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.46 L Cr | 84.1 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.92 L Cr | 80.3 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.18 L Cr | 26.4 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.15 L Cr | 34.0 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.05 L Cr | 95.5 | 20.8% | 20.6% | 0.45 |
| LUPIN | 99,448 | 17.6 | 27.9% | 24.7% | 0.26 |
| MANKIND | 98,599 | 48.2 | 13.9% | 12.7% | 0.38 |
| DRREDDY | 98,308 | 30.4 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 94,937 | 25.8 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Integration risks from the JB Pharma acquisition could materialize if synergies are not fully realized or if unexpected liabilities emerge, as evidenced by the ₹21 crores in exceptional items during Q1 FY27. 2. High valuation multiples (P/E of 80.3) may limit upside if growth slows or margin compression occurs, especially given increasing competition in key markets like Brazil and the US. 3. Currency volatility, particularly in the Brazilian Real and US Dollar, could impact reported earnings despite strong underlying demand. 4. Regulatory and pricing pressures in global pharmaceutical markets pose a persistent challenge to margin sustainability, even as the company expands its footprint.
📋 Recent Filings
-
Announcement 11 August 2026Torrent Pharmaceuticals announced its participation in an investors' meet hosted by Emkay on August 14, 2026, in Mumbai, as part of Regulation 30 comp...
-
Announcement 11 August 2026Torrent Pharmaceuticals announced that NSE Sustainability Ratings and Analytics assigned the company an ESG rating of 70, reflecting its environmental...
-
🔴 Financial Results 4 August 2026Torrent Pharmaceuticals announced a conference call transcript for Q1 FY26 results on August 4, 2026, inviting analysts and institutional investors to...
-
🟡 Board Meeting 1 August 2026Torrent Pharmaceuticals announced the cessation of Ameera Shah as an Independent Director effective 01-Aug-2026, following completion of her term as p...
-
🔴 Financial Results 30 July 2026Torrent Pharmaceuticals announced that the audio recording of its conference call discussing financial results for the quarter ended June 30, 2026, is...
-
🟡 Board Meeting 30 July 2026Torrent Pharmaceuticals reported consolidated revenue of **₹4,921 crores** (+55% YoY) and net profit of **₹566 crores** (+3% YoY) for Q1 FY27, driven ...
-
Announcement 30 July 2026Torrent Pharmaceuticals announced the departure of three senior management personnel—Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni—effective July ...
-
🔴 Financial Results 30 July 2026Torrent Pharmaceuticals reported record Q1 FY27 revenue of **₹4,921 crores**, up **55% YoY**, driven by organic growth and the JB Pharma acquisition, ...
-
🟡 Board Meeting 28 July 2026Torrent Pharmaceuticals announced the appointment of Shanti Ekambaram as an Additional Independent Director effective 30 July 2026 for a three-year te...
-
🔴 Corporate Action 27 July 2026Torrent Pharmaceuticals announced final listing and trading approval for 4,19,22,416 fully paid-up equity shares resulting from the amalgamation with ...
🧠 Analyst's Read
Torrent Pharmaceuticals is executing a clear growth strategy with strong top-line momentum and improving profitability, supported by successful acquisitions and regional diversification. The key watchpoint is whether the current growth trajectory can be sustained without further large-scale acquisitions or if margin pressure emerges from pricing or currency headwinds. Investors should monitor management’s ability to deliver consistent earnings visibility beyond exceptional items and the pace of integration in Brazil and CDMO segments.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when TORNTPHARM files new disclosures
Track TORNTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track TORNTPHARM — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd